FIBROCELL SCIENCE, INC. (NASDAQ:FCSC) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
Science, Inc. (the Company) appointed Lisa A. Embon, age 53, as
Vice President of Corporate Accounting and Controller of the
Company and designated her as the Companys principal financial
officer and principal accounting officer, effective immediately.
with AC Lordi (AC Lordi), dated as of May 8, 2017 and an
accompanying addendum (collectively, the Engagement Letter). to
the terms of the Engagement Letter, AC Lordi assigned the
services of Ms. Embon to the Company to, among other things,
assume the responsibilities of Vice President of Corporate
Accounting and Controller of the Company, serve as the Companys
principal financial officer and principal accounting officer,
assume the responsibilities for the accounting operations of the
Company and execute documents on behalf of the Company as
directed by the Chief Executive Officer of the Company and/or the
Board. The Company expects to pay AC Lordi an estimated $37,000
per month for Ms. Embons services. In addition, the Company will
reimburse AC Lordi for any reasonable, service-related and
out-of-pocket travel expenses incurred by Ms. Embon in the course
of her service with the Company. The Engagement Letter may be
terminated by either party upon 30 days prior written notice.
Lordi since September 2009. Ms. Embon joined AC Lordi in 2003 and
became a Principal, Accounting Services of AC Lordi in 2015.
Prior to her work with the Company, Ms. Embon provided audit and
business advisory services to companies ranging from private
start-ups to multinational corporations in the life sciences,
manufacturing and healthcare industries. Ms. Embon held key
accounting positions for AC Lordi clients, including SEC
Reporting Manager, Director of Accounting Finance, and
Controller. Prior to joining AC Lordi, Ms. Embon worked at
PricewaterhouseCoopers, LLC from 1986 to 1993. Ms. Embon earned a
B.A. in Business Administration from Gettysburg College.
incorporated herein by reference. The foregoing description of
the terms of the Engagement Letter is qualified in its entirety
by reference to such exhibit.
director or executive officer of the Company, and she has no
direct or indirect material interest in any transaction required
to be disclosed to Item 404(a) of Regulation S-K.
|
Exhibit No.
|
Description
|
|
|
10.1
|
Engagement Letter, dated May 8, 2017, by and between
Fibrocell Science, Inc. and AC Lordi |
About FIBROCELL SCIENCE, INC. (NASDAQ:FCSC)
Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults. FIBROCELL SCIENCE, INC. (NASDAQ:FCSC) Recent Trading Information
FIBROCELL SCIENCE, INC. (NASDAQ:FCSC) closed its last trading session down -0.02 at 1.80 with 47,398 shares trading hands.
